NCI/CTEP #9149: Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors

Print this page

NCI/CTEP #9149: Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors

Compare the response rate (complete response (CR) plus partial response (PR) and 4-month progression-free survival (PFS) for treatment with agents chosen based on the presence of specific mutations in patient tumors with the response rate for treatment with agents chosen from the complementary set of agents not identified to target the mutations of interest.

Protocol Number: 051705
Phase: Phase I/II
Applicable Disease Sites: Any Site
Drugs Involved: RAD001 (Everolimus)
ABT-888(Veliparib)
AZD1775(MK-1775)
CARBOPLATIN
Trametinib
Principal Investigator: Kim Hirshfield
Scope: National
Therapies Involved: Chemotherapy (NOS)
Participating Institutions: Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health